THE RETROVIRAL VECTOR - REPLICATION CYCLE AND SAFETY CONSIDERATIONS FOR RETROVIRUS-MEDIATED GENE-THERAPY
THE RETROVIRAL VECTOR - REPLICATION CYCLE AND SAFETY CONSIDERATIONS FOR RETROVIRUS-MEDIATED GENE-THERAPY
复制标题
DOI：
10.1111/j.1749-6632.1994.tb21703.x
复制
发表时间：
1994-01-01
期刊：
影响因子：
--
通讯作者：
TEMIN, HM
中科院分区：
文献类型：
--
作者：
BORISLAWRIE, K;TEMIN, HM
逆转录病毒独特的复制周期使它们成为基因治疗的载体;迄今为止，大多数人类基因治疗试验都使用逆转录病毒载体。然而，从长远来看，逆转录病毒复制的两个特性导致了逆转录病毒介导的基因治疗的安全性问题：遗传变异率高和前病毒随机整合到宿主染色体中。原则上，逆转录病毒介导的基因治疗的获益与逆转录病毒载体感染相关风险之间的平衡评估与使用化疗药物治疗癌症的获益-风险平衡评估相似。我们将讨论逆转录病毒复制周期背景下逆转录病毒介导的基因治疗的安全性考虑。此外，我们将介绍一种新的方法，我们正在开发使用逆转录病毒载体，以防止由逆转录病毒引起的疾病。逆转录病毒载体疫苗的安全性考虑与逆转录病毒介导的基因治疗相似。
The unique replication cycle of retroviruses makes them us& as vectors for gene therapy; most human gene therapy trials to date have used retroviral vectors.'However, in the long term two properties of retroviral replication lead to safety concerns about retrovirus-mediated gene therapy: the high rate of genetic variability and the random integration of the provirus into the host chromosome. The assessment of the balance between the benefits of retrovirusmediated gene therapy and the risk associated with infection with a retroviral vector is similar, in principle, to the assessment of the benefit-risk balance of using chemotherapeutic agents to treat cancer. We will discuss safety considerations for retrovirus-mediated gene therapy in the context of the retroviral replication cycle. Also, we will present a new approach that we are developing for using retroviral vectors to prevent diseases caused by retroviruses. The safety considerations for retroviral vector vaccines are similar to those for retrovirus-mediated gene therapy.